Cerenome Launches New Corporate Identity as Integrated CNS Oncology Company

NEW YORK, NY, August 27th, 2026, FinanceWire

Watch the Full Cerenome FINTECH.TV Interview HERE 

Cerenome, Inc. is officially launching its new corporate identity, marking the next phase in the company’s evolution from a therapeutics-focused biotechnology company into an integrated CNS oncology organization.

Effective August 3, 2026, the company will begin trading on the Nasdaq Capital Market under the new ticker CNSY, following its rebrand from Plus Therapeutics, Inc. (Nasdaq: PSTV).

The rebrand reflects Cerenome’s broader strategy to address central nervous system cancers through an integrated model combining precision diagnostics, targeted therapeutics and advanced data analytics. The company believes that improving outcomes in CNS oncology requires more than treating tumors in isolation and instead demands a comprehensive understanding of disease biology across diagnosis, treatment and ongoing patient management.

“The name change is a capstone to what we’ve been doing over the last two or three years. The company has evolved from a single-drug radiotherapeutic company to adding a CSF diagnostic platform, and now AI leveraging the enormous data sets we’ve merged from the therapeutic and diagnostic sides,” said Dr. Hedrick, M.D., President and Chief Executive Officer of Cerenome, in his FINTECH.TV interview.

Cerenome’s platform is built around three complementary areas:

• CNSide Diagnostic — A commercially available and reimbursed cerebrospinal fluid-based diagnostic platform designed to characterize cellular and multiomic information to support the diagnosis and management of patients with, or at risk for, CNS cancers.
• REYOBIQ (rhenium Re186 obisbemeda) — The company’s lead investigational targeted radiotherapeutic, currently being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma and pediatric brain cancer.
• Data Analytics and Artificial Intelligence — A proprietary platform intended to integrate diverse datasets into actionable insights supporting precision oncology, drug development and clinical decision-making.

The company’s strategy is designed to connect these capabilities across the patient journey, from earlier disease detection and characterization through targeted treatment and longitudinal monitoring.

Cerenome (Nasdaq: CNSY) is also positioning the integrated platform as a foundation for collaboration with healthcare providers, academic institutions and biopharmaceutical companies, creating potential opportunities across research, clinical development and precision oncology.

According to Hedrick, the company’s name reflects this broader vision. “Cere” represents the brain and central nervous system, while “nome” reflects the expansive knowledge sets that underpin the company’s precision oncology strategy.

While the corporate identity and Nasdaq ticker are changing, Cerenome’s existing CNSide and REYOBIQ product brands will remain unchanged.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value.

About FINTECH.TV

FINTECH.TV is a global financial media company delivering real-time coverage of financial markets, capital formation, financial technology, digital assets and global economic trends. The company operates live studios at the New York Stock Exchange and Abu Dhabi Securities Exchange and provides programming, market intelligence, live streaming and executive visibility across major global financial centers.

For broadcast partnership and sponsorship inquiries, email us at partnerships@fintech.tv 

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding the effectiveness of the Company’s expected name change and ticker symbol change, the anticipated date of trading of the Company’s common stock on the Nasdaq Capital Market under its new ticker symbol, clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the receipt of necessary regulatory approvals. 

Sponsored Content Disclaimer

This content was prepared and distributed on behalf of Cerenome, Inc. and is sponsored content. It is provided for informational purposes only and does not constitute an endorsement, investment recommendation, or offer or solicitation to buy or sell any security. The information presented has been provided by the sponsor and has not been independently verified. Readers should conduct their own due diligence and consult with qualified professional advisors before making any investment decision.

Investor Contact

CORE IR

investor@plustherapeutics.com

Media Contact 

FINTECH.TV 

partnerships@fintech.tv 

Contact

FINTECH.TV
partnerships@fintech.tv

Disclaimer. This is a paid press release.